Product Portfolio

Novast currently holds a strong portfolio of oral contraceptive products available in the USA market and have several ANDAs for sustained release products submitted to the USFDA. Novast also submitted products to the China FDA and currently in process to develop a large pipeline of products for both the regulatory agencies. Novast signed a development and supply agreement with Eli Lilly and company in 2012 to jointly develop and commercialize several branded products in the China market. Novast successfully fulfilled an extensive due diligence of the quality systems and manufacturing capabilities by Lilly before the execution of the contract.
Quality Systems
Our Novast teams are multinational groups of experienced professionals from countries including the China, United States, Canada and India. More...
Web Design and Development in Hyderabad
Strategy
Novast's business model utilizes our extensive expertise, experience and proven ability in product research & development and manufacturing. More...
Business Solutions Provider
Our Investors
We are supported by the following global investors

More...
Business Solutions